---
title: "Insmed reports positive 12-month TPIP extension data in pulmonary arterial hypertension study"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292894573.md"
description: "Insmed reported positive 12-month open-label extension data for once-daily TPIP in pulmonary arterial hypertension, supporting late-stage development. Key results included a ~55-meter increase in 6-minute walk distance and a ~60% drop in NT-proBNP. Approximately 65% of patients achieved refined low-risk status by month 12. The safety profile remained consistent with no new signals. Phase 3 PALM-PAH trial has started."
datetime: "2026-07-16T11:03:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292894573.md)
  - [en](https://longbridge.com/en/news/292894573.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292894573.md)
---

# Insmed reports positive 12-month TPIP extension data in pulmonary arterial hypertension study

-   Insmed reported positive 12-month open-label extension data for once-daily TPIP in pulmonary arterial hypertension, supporting continued late-stage development. \* 6-minute walk distance rose about 55 meters from baseline in both TPIP-continued and placebo-crossed groups; NT-proBNP fell about 60%. \* About 65% of patients reached refined low-risk status on REVEAL Lite 2.0 by month 12; scores improved 2 points or 1.4 points. \* Safety profile stayed consistent through month 12 with no new signals; 7.7% discontinued; four deaths were reported, none treatment-related. \* Phase 3 PALM-PAH started; primary endpoint is change in 6-minute walk distance over 24 weeks. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insmed Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607160700PR\_NEWS\_USPR\_\_\_\_\_NY05956) on July 16, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [INSM.US](https://longbridge.com/en/quote/INSM.US.md)

## Related News & Research

- [Top Insmed Executive Executes Major Multi-Million Dollar Stock Move](https://longbridge.com/en/news/295744066.md)
- [Insmed COO Roger Adsett sells 239,850 shares for $31.97 million](https://longbridge.com/en/news/295709972.md)
- [$1000 Invested In Insmed 5 Years Ago Would Be Worth This Much Today](https://longbridge.com/en/news/295430649.md)
- [13,000 Shares in Insmed, Inc. $INSM Purchased by S&CO Inc.](https://longbridge.com/en/news/296021707.md)
- [Cereno Scientific activates first site for Phase IIb EPIMODE trial of CS1 in pulmonary arterial hypertension](https://longbridge.com/en/news/295750138.md)